Physician profile
Emma Babayan
NPI 1861460016
$2,210.72
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $107 · 2022: $363 · 2023: $655 · 2024: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $359.73 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $262.93 | 2019-2024 | Rybelsus, Wegovy, Saxenda |
| Abbvie INC. | $261.84 | 2019-2024 | Qulipta |
| Pfizer INC. | $146.54 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $139.14 | 2023-2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $138.54 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $111.77 | 2022-2024 | |
| Lilly USA, LLC | $104.55 | 2019-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $102.52 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.60 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.22 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $63.95 | 2024 | Prolia, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $53.61 | 2019-2022 | |
| Astellas Pharma US INC | $37.99 | 2023-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $24.56 | 2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.55 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.88 | 2022 | |
| Inspire Medical Systems, INC. | $22.30 | 2024 | Inspire |
| Medtronic, INC. | $22.08 | 2023 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $21.52 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.23 | 2023 | |
| Paratek Pharmaceuticals, INC. | $20.33 | 2023 | Nuzyra |
| Abbott Laboratories | $18.78 | 2022 | |
| Kyowa Kirin, INC. | $17.61 | 2024 | Crysvita |
| Allergan, INC. | $16.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Babayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.